Contact this trialFirst, we need to learn more about you.
Antibody-Drug Conjugate
U3-1402 for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1
Seattle, Washington
This trial will study U3-1402, a new drug for treating non-small cell lung cancer. The study will evaluate safety and effectiveness in two parts: dose escalation and dose expansion.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.